Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12833644 | 0.86 | TBXAS1 (0.51) | TBXAS1CDC25ACDC25BMAPTMEN1 | |
| SCHEMBL12833654 | 0.81 | MAPT (0.65) | TBXAS1NR1H3CDC25ACDC25BMAPT | |
| SCHEMBL1506990 | 0.80 | TBXAS1 (0.55) | TBXAS1NR1H3NR1H2CDC25ACDC25B | |
| SCHEMBL12833655 | 0.79 | TBXAS1 (0.54) | TBXAS1CDC25ACDC25BMAPTMEN1 | |
| SCHEMBL12822495 | 0.78 | ACHE (0.41) | CA2TBXAS1MAPTMEN1KMT2A | |
| SCHEMBL12834582 | 0.78 | CDC25A (0.45) | TBXAS1CDC25ACDC25BMAPTMEN1 | |
| SCHEMBL12833641 | 0.78 | CDC25A (0.51) | TBXAS1CDC25ACDC25BMAPTMEN1 | |
| SCHEMBL29906354 | 0.78 | TBXAS1 (0.55) | TBXAS1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL26982490 | 0.78 | TBXAS1 (0.55) | TBXAS1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL29906409 | 0.77 | TBXAS1 (0.60) | TBXAS1CDC25ACDC25BMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615502-B1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIV TASMANIA (AU) | 2023-06-21 | — | — | EP | disclosed |
| US-10934253-B2 | Therapeutic compounds and methods | UNIVERSITY OF TASMANIA (AU) | 2021-03-02 | — | — | US | disclosed |
| US-20200131119-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF TASMANIA (AU) | 2020-04-30 | — | — | US | disclosed |
| EP-2257515-B1 | 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-9090549-B2 | 1,4-naphthoquinones derivatives and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-07-28 | — | — | US | disclosed |
| US-20110059972-A1 | 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131119-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UQCRC1, COX5B, CS | CA2 1193/4885TBXAS1 993/4885NR1H3 516/4885 |
| US-20110059972-A1 | 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF | NQO1, NDUFV2, RECQL | CA2 4747/4885TBXAS1 183/4885NR1H3 132/4885 |
| US-10934253-B2 | Therapeutic compounds and methods | UQCRC1, COX5B, CS | CA2 1193/4885TBXAS1 993/4885NR1H3 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.